|
US5759833A
(en)
|
1994-05-27 |
1998-06-02 |
Cubist Pharmaceuticals, Inc. |
Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
|
|
DE69926052T2
(de)
|
1998-01-14 |
2006-04-27 |
Human Gene Therapy Research Institute |
Menschliche Suppressor-tRNA Oligonukleotide Verfahren für deren Verwendung
|
|
US6844148B1
(en)
*
|
1998-09-24 |
2005-01-18 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
|
NZ522840A
(en)
|
2000-06-01 |
2004-12-24 |
Univ North Carolina |
A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
|
|
WO2004094593A2
(en)
|
2003-04-17 |
2004-11-04 |
The Scripps Research Institute |
Expanding the eukaryotic genetic code
|
|
JP5275566B2
(ja)
|
2003-06-18 |
2013-08-28 |
ザ スクリプス リサーチ インスティチュート |
反応性非天然アミノ酸遺伝コード付加
|
|
US8314226B2
(en)
|
2004-03-29 |
2012-11-20 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
AU2007282224B2
(en)
|
2006-08-11 |
2013-08-29 |
Vico Therapeutics B.V. |
Methods and means for treating DNA repeat instability associated genetic disorders
|
|
KR101507402B1
(ko)
|
2007-05-31 |
2015-04-02 |
노보자임스 인코포레이티드 |
폴리펩티드의 셀룰로오스 가수분해 증진 활성을 증가시키는 방법
|
|
WO2012161144A1
(ja)
|
2011-05-20 |
2012-11-29 |
学校法人 福岡大学 |
Rna配列上の修飾を識別するリボザイムおよびそれを用いたrna開裂方法
|
|
HUE048622T2
(hu)
|
2011-11-18 |
2020-08-28 |
Alnylam Pharmaceuticals Inc |
RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
|
|
SMT201700339T1
(it)
|
2012-04-23 |
2017-09-07 |
Biomarin Tech Bv |
Oligonucleotidi di modulazione dell'rna con caratteristiche migliorate per il trattamento dei disturbi neuromuscolari
|
|
EP2852668B1
(en)
|
2012-07-12 |
2016-04-27 |
ProQR Therapeutics II B.V. |
Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
|
|
US9650627B1
(en)
|
2012-07-19 |
2017-05-16 |
University Of Puerto Rico |
Site-directed RNA editing
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
DK3041854T3
(da)
|
2013-08-08 |
2020-03-02 |
Scripps Research Inst |
En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
|
|
PL3041958T4
(pl)
|
2013-09-04 |
2020-11-02 |
Cold Spring Harbor Laboratory |
Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2015120197A1
(en)
|
2014-02-05 |
2015-08-13 |
Regents Of The University Of California |
Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer
|
|
US10513706B2
(en)
|
2014-04-09 |
2019-12-24 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
|
EP3140403A4
(en)
*
|
2014-05-09 |
2017-12-20 |
Université Laval |
Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
|
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
|
EP4372091A3
(en)
*
|
2014-12-12 |
2024-07-31 |
Tod M. Woolf |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
US10676737B2
(en)
*
|
2014-12-17 |
2020-06-09 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
GB201503408D0
(en)
|
2015-02-27 |
2015-04-15 |
Proqr Therapeutics N V |
Oligonucleotides
|
|
GB201504124D0
(en)
|
2015-03-11 |
2015-04-22 |
Proqr Therapeutics B V |
Oligonucleotides
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
JP6624743B2
(ja)
|
2015-07-14 |
2019-12-25 |
学校法人福岡大学 |
部位特異的ｒｎａ変異導入方法およびそれに使用する標的編集ガイドｒｎａならびに標的ｒｎａ−標的編集ガイドｒｎａ複合体
|
|
US11479793B2
(en)
|
2015-07-15 |
2022-10-25 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
CN108135921B
(zh)
|
2015-07-22 |
2023-10-17 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2017040477A1
(en)
|
2015-08-31 |
2017-03-09 |
The University Of Chicago |
Composition and methods for detecting adenosine modifications
|
|
DE102015012522B3
(de)
|
2015-09-26 |
2016-06-02 |
Eberhard Karls Universität Tübingen |
Verfahren und Substanzen zur gerichteten RNA-Editierung
|
|
EP3359667A1
(en)
|
2015-10-05 |
2018-08-15 |
ProQR Therapeutics II B.V. |
Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
CA3000046A1
(en)
|
2015-10-16 |
2017-04-20 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for use in treating alzheimer's disease
|
|
US10370667B2
(en)
|
2015-11-18 |
2019-08-06 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
|
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
|
IL261713B2
(en)
*
|
2016-03-19 |
2023-09-01 |
F1 Oncology Inc |
Methods and preparations for the transfer of lymphocytes and their regulated expansion
|
|
CN109414451B
(zh)
|
2016-05-16 |
2022-08-12 |
德克萨斯大学系统董事会 |
用于作为纳米粒递送tRNA的组合物及其使用方法
|
|
CA3028158A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute, Inc. |
Type vi crispr orthologs and systems
|
|
EP3475424A1
(en)
*
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
EP3487998B1
(en)
|
2016-07-19 |
2023-07-12 |
Brandeis University |
Compositions and methods for identifying rna binding polypeptide targets
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
US10831743B2
(en)
|
2016-09-02 |
2020-11-10 |
PFFA Acquisition LLC |
Database and system architecture for analyzing multiparty interactions
|
|
GB201616202D0
(en)
|
2016-09-23 |
2016-11-09 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of eye deisease
|
|
WO2018129129A1
(en)
|
2017-01-05 |
2018-07-12 |
Rutgers, The State University Of New Jersey |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
|
US11274300B2
(en)
|
2017-01-19 |
2022-03-15 |
Proqr Therapeutics Ii B.V. |
Oligonucleotide complexes for use in RNA editing
|
|
GB2574769A
(en)
|
2017-03-03 |
2019-12-18 |
Univ California |
RNA Targeting of mutations via suppressor tRNAs and deaminases
|
|
GB201706009D0
(en)
|
2017-04-13 |
2017-05-31 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of stargardt disease
|
|
EP3622062A4
(en)
|
2017-05-10 |
2020-10-14 |
The Regents of the University of California |
DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
|
|
WO2018213708A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
US11756183B2
(en)
|
2017-06-23 |
2023-09-12 |
Cornell University |
RNA molecules, methods of producing circular RNA, and treatment methods
|
|
AU2018290843B2
(en)
|
2017-06-26 |
2025-04-24 |
Massachusetts Institute Of Technology |
CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
MA49716A
(fr)
|
2017-07-11 |
2021-04-07 |
Scripps Research Inst |
Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
|
|
AU2018300069C1
(en)
|
2017-07-11 |
2025-11-20 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
US10476825B2
(en)
|
2017-08-22 |
2019-11-12 |
Salk Institue for Biological Studies |
RNA targeting methods and compositions
|
|
GB201714027D0
(en)
|
2017-09-01 |
2017-10-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
WO2019071048A1
(en)
*
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION
|
|
EP4389889A3
(en)
|
2017-10-06 |
2024-09-04 |
Oregon Health & Science University |
Compositions and methods for editing rna
|
|
US20210130800A1
(en)
|
2017-10-23 |
2021-05-06 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
CA3081705A1
(en)
|
2017-11-07 |
2019-05-16 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for circular rna molecules
|
|
WO2019104094A2
(en)
|
2017-11-21 |
2019-05-31 |
The Regents Of The University Of California |
Fusion proteins and methods for site-directed genome editing
|
|
JP7333508B2
(ja)
|
2017-12-06 |
2023-08-25 |
学校法人福岡大学 |
オリゴヌクレオチド、その製造方法及び標的ｒｎａの部位特異的編集方法
|
|
WO2019158475A1
(en)
|
2018-02-14 |
2019-08-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for rna editing
|
|
GB201803010D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Royal Holloway & Bedford New College |
Neurodegenerative disorders
|
|
AU2019266327B2
(en)
|
2018-05-11 |
2025-11-06 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2020001793A1
(en)
|
2018-06-29 |
2020-01-02 |
Eberhard-Karls-Universität Tübingen |
Artificial nucleic acids for rna editing
|
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
|
SG11202100750XA
(en)
|
2018-07-24 |
2021-02-25 |
Flagship Pioneering Innovations Vi Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
AU2019336793B2
(en)
|
2018-09-06 |
2024-11-21 |
The Regents Of The University Of California |
RNA and DNA base editing via engineered ADAR recruitment
|
|
EP4306116A3
(en)
|
2018-10-12 |
2024-04-17 |
Peking University |
Methods and compositions for editing rnas
|
|
JP2022513159A
(ja)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド |
Ｒｎａを調節する方法
|
|
SG11202105626TA
(en)
|
2018-12-06 |
2021-06-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
BR102019009665A2
(pt)
*
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
|
AU2019419494B2
(en)
|
2018-12-31 |
2026-03-26 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
|
TW202043469A
(zh)
|
2019-01-22 |
2020-12-01 |
美商科羅生物公司 |
Ｒｎａ編輯之寡核苷酸及其用途
|
|
KR20210129646A
(ko)
|
2019-01-22 |
2021-10-28 |
코로 바이오, 인크. |
Rna-편집 올리고뉴클레오타이드 및 그의 용도
|
|
EP3914261A4
(en)
|
2019-01-22 |
2023-06-28 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
AU2020215232A1
(en)
|
2019-01-28 |
2021-08-26 |
Proqr Therapeutics Ii B.V. |
RNA-editing oligonucleotides for the treatment of usher syndrome
|
|
US20220098584A1
(en)
|
2019-01-28 |
2022-03-31 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of leber`s congenital amaurosis
|
|
KR20210121199A
(ko)
|
2019-02-01 |
2021-10-07 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
GB201901873D0
(en)
|
2019-02-11 |
2019-04-03 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for nucleic acid editing
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
GB201904709D0
(en)
|
2019-04-03 |
2019-05-15 |
Proqr Therapeutics Ii Bv |
Chemically modified oligonucleotides
|
|
KR102851101B1
(ko)
|
2019-04-15 |
2025-08-27 |
에디진 테라퓨틱스(베이징) 인크. |
Rna를 편집하기 위한 방법 및 조성물
|
|
AU2020259856A1
(en)
|
2019-04-18 |
2021-11-18 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of usher syndrome
|
|
GB201905732D0
(en)
|
2019-04-24 |
2019-06-05 |
Proqr Therapeutics Ii Bv |
RNA editing inhibitors and methods of use
|
|
CA3140438A1
(en)
|
2019-06-05 |
2020-12-10 |
Masatora Fukuda |
Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
|
|
WO2020252376A1
(en)
|
2019-06-13 |
2020-12-17 |
Proqr Therapeutics Ii B.V. |
Antisense rna editing oligonucleotides comprising cytidine analogs
|
|
WO2020254249A1
(en)
|
2019-06-21 |
2020-12-24 |
Proqr Therapeutics Ii B.V. |
Delivery of nucleic acids for the treatment of auditory disorders
|
|
PE20220300A1
(es)
|
2019-07-12 |
2022-03-09 |
Univ Beijing |
Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
|
|
WO2021018750A1
(en)
|
2019-07-26 |
2021-02-04 |
Proqr Therapeutics Ii B.V. |
Ophthalmic compositions comprising viscosifying polymers and nucleic acids
|
|
EP4008784A1
(en)
|
2019-08-01 |
2022-06-08 |
Astellas Pharma Inc. |
Guide rna for targeted-editing with functional base sequence added thereto
|
|
EP4036230A4
(en)
|
2019-09-27 |
2024-03-06 |
Frest Inc. |
OLIGONUCLEOTIDE AND TARGET RNA SITE-SPECIFIC EDITING METHOD
|
|
WO2021113270A1
(en)
|
2019-12-02 |
2021-06-10 |
Shape Therapeutics Inc. |
Therapeutic editing
|
|
MX2022006991A
(es)
|
2019-12-09 |
2022-08-25 |
Astellas Pharma Inc |
Arn guía antisentido con región funcional añadida para editar arn blanco.
|
|
CA3158528A1
(en)
|
2019-12-23 |
2021-07-01 |
Jim SWILDENS |
Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease
|
|
MX2022008197A
(es)
|
2019-12-30 |
2022-08-02 |
Edigene Therapeutics Beijing Inc |
Metodo para el tratamiento del sindrome de usher y composicion del mismo.
|
|
IL294201A
(en)
|
2019-12-30 |
2022-08-01 |
Edigene Therapeutics Beijing Inc |
A method based on leaper technology to treat mps ih and a preparation
|
|
AU2020417930A1
(en)
|
2019-12-31 |
2022-08-18 |
Edigene Therapeutics (Beijing) Inc. |
New method for targeted editing of RNA
|
|
CA3166720A1
(en)
|
2020-03-04 |
2021-09-10 |
Jim SWILDENS |
Antisense oligonucleotides for use in the treatment of usher syndrome
|
|
PE20230703A1
(es)
|
2020-04-15 |
2023-04-24 |
Edigene Therapeutics Beijing Inc |
Metodo y farmaco para tratar el sindrome de hurler
|
|
CN115777020A
(zh)
|
2020-04-22 |
2023-03-10 |
塑造治疗公司 |
使用snrna组分的组合物和方法
|
|
US20230174977A1
(en)
|
2020-05-26 |
2023-06-08 |
Shape Therapeutics Inc. |
Engineered circular polynucleotides
|
|
WO2021261957A1
(ko)
|
2020-06-26 |
2021-12-30 |
애터미주식회사 |
스마트 칫솔 및 스마트 살균기를 포함하는 구강 관리 시스템
|
|
WO2022119975A2
(en)
|
2020-12-01 |
2022-06-09 |
Shape Therapeutics Inc. |
High throughput rna-editing screening methods
|